BR112015000942A2 - uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular - Google Patents

uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular

Info

Publication number
BR112015000942A2
BR112015000942A2 BR112015000942A BR112015000942A BR112015000942A2 BR 112015000942 A2 BR112015000942 A2 BR 112015000942A2 BR 112015000942 A BR112015000942 A BR 112015000942A BR 112015000942 A BR112015000942 A BR 112015000942A BR 112015000942 A2 BR112015000942 A2 BR 112015000942A2
Authority
BR
Brazil
Prior art keywords
inhibitors
hepatocellular carcinoma
vegfr
treat hepatocellular
treatment
Prior art date
Application number
BR112015000942A
Other languages
English (en)
Inventor
Alam Antoine
Blanc Isabelle
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112015000942A2 publication Critical patent/BR112015000942A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo patente de invenção: "uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular". a presente invenção refere-se ao uso de inibidores do receptor de fator de crescimento endotelial vascular 3 para tratamento do carcinoma hepatocelular. 1/1
BR112015000942A 2012-07-17 2013-07-16 uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular BR112015000942A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672489P 2012-07-17 2012-07-17
EP12305866 2012-07-17
PCT/EP2013/065029 WO2014012942A1 (en) 2012-07-17 2013-07-16 Use of vegfr-3 inhibitors for treating hepatocellular carcinoma

Publications (1)

Publication Number Publication Date
BR112015000942A2 true BR112015000942A2 (pt) 2017-06-27

Family

ID=49948312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015000942A BR112015000942A2 (pt) 2012-07-17 2013-07-16 uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular

Country Status (31)

Country Link
US (1) US9376432B2 (pt)
EP (1) EP2874625B1 (pt)
JP (1) JP6226981B2 (pt)
KR (1) KR102068860B1 (pt)
CN (1) CN104602691B (pt)
AU (1) AU2013292054B2 (pt)
BR (1) BR112015000942A2 (pt)
CA (1) CA2878987C (pt)
CL (1) CL2015000115A1 (pt)
CR (1) CR20150029A (pt)
CY (1) CY1119415T1 (pt)
DK (1) DK2874625T3 (pt)
EA (1) EA027982B1 (pt)
ES (1) ES2635105T3 (pt)
HK (1) HK1206257A1 (pt)
HR (1) HRP20171227T1 (pt)
HU (1) HUE035712T2 (pt)
IL (1) IL236718A (pt)
LT (1) LT2874625T (pt)
MA (1) MA37821A1 (pt)
MX (1) MX367402B (pt)
PH (1) PH12015500094A1 (pt)
PL (1) PL2874625T3 (pt)
PT (1) PT2874625T (pt)
RS (1) RS56178B1 (pt)
SG (1) SG11201500156SA (pt)
SI (1) SI2874625T1 (pt)
TN (1) TN2015000021A1 (pt)
TW (1) TW201406759A (pt)
WO (1) WO2014012942A1 (pt)
ZA (1) ZA201500182B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
WO2014026242A1 (en) 2012-08-17 2014-02-20 Cancer Therapeutics Crc Pty Limited Vegfr3 inhibitors
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2760456B1 (fr) * 1997-03-05 2000-05-12 Sanofi Sa Procede de preparation de derives de 2-thienyl-ethylamine
US5994367A (en) 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
CN1191252C (zh) * 2003-08-11 2005-03-02 中国药科大学 3－位取代的喹诺酮衍生物及其在药学上的应用
AU2004288709B2 (en) * 2003-11-07 2011-01-06 Novartis Vaccines And Diagnostics, Inc. Methods for synthesizing quinolinone compounds
CN1325494C (zh) * 2005-08-18 2007-07-11 中国药科大学 3－位取代的萘啶酮类化合物及其制备方法和在制药中的应用
KR100744826B1 (ko) * 2006-04-05 2007-08-01 한국화학연구원 이미다졸기가 치환된 퀴놀리논 유도체
FR2917412B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933701A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
WO2010073078A2 (en) 2008-12-22 2010-07-01 Orchid Research Laboratories Ltd. Heterocyclic compounds as hdac inhibitors
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors

Also Published As

Publication number Publication date
LT2874625T (lt) 2017-08-25
EP2874625B1 (en) 2017-05-17
CL2015000115A1 (es) 2015-05-04
WO2014012942A1 (en) 2014-01-23
MA37821A1 (fr) 2018-02-28
HUE035712T2 (en) 2018-05-28
CA2878987C (en) 2020-07-21
KR102068860B1 (ko) 2020-01-21
ES2635105T3 (es) 2017-10-02
US20150183780A1 (en) 2015-07-02
EA201590229A1 (ru) 2015-05-29
HK1206257A1 (en) 2016-01-08
HRP20171227T1 (hr) 2017-10-20
PH12015500094A1 (en) 2015-03-02
MX367402B (es) 2019-08-20
RS56178B1 (sr) 2017-11-30
CY1119415T1 (el) 2018-03-07
TN2015000021A1 (en) 2016-06-29
DK2874625T3 (en) 2017-09-11
TW201406759A (zh) 2014-02-16
IL236718A (en) 2017-11-30
PL2874625T3 (pl) 2017-10-31
CR20150029A (es) 2015-04-06
EP2874625A1 (en) 2015-05-27
AU2013292054A1 (en) 2015-02-05
CN104602691A (zh) 2015-05-06
SI2874625T1 (sl) 2017-10-30
CA2878987A1 (en) 2014-01-23
JP6226981B2 (ja) 2017-11-08
US9376432B2 (en) 2016-06-28
CN104602691B (zh) 2016-12-28
MX2015000797A (es) 2015-08-13
ZA201500182B (en) 2015-12-23
EA027982B1 (ru) 2017-09-29
KR20150036401A (ko) 2015-04-07
IL236718A0 (en) 2015-02-26
AU2013292054B2 (en) 2017-08-03
PT2874625T (pt) 2017-08-16
JP2015522598A (ja) 2015-08-06
SG11201500156SA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
IL230561A0 (en) Broton tyrosine kinase inhibitors
EA201500362A1 (ru) Ингибиторы rho-киназы
DE202012013074U8 (de) Zusammensetzungen zur Behandlung von HCV
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
DK2734212T3 (da) Sammensætninger omfattende diclofenac til behandling af postoperativ smerte
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
IT1406864B1 (it) Composizione per il trattamento dell'acne
BR112015000942A2 (pt) uso de inibidores de vegfr-3 para tratamento de carcinoma hepatocelular
ITRM20120405A1 (it) Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
IL229424A0 (en) Pharmaceutical preparations containing neuropilin inhibitors and their uses in the prevention and/or treatment of angiogenic disorders and cancer
BR112013030930A2 (pt) composições farmacêuticas combinadas para o tratamento de tumores
PH12015501179A1 (en) Fixed dose pharmaceutical composition comprising mometasone and azelastine
FR2963738B1 (fr) Compose destine au traitement des douleurs abdominales fonctionnelles
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]